Deutsche Bank’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-12,730
| Closed | -$609K | – | 3730 |
|
|
2025
Q3 | $609K | Sell |
12,730
-1,948
| -13% | -$54K | ﹤0.01% | 2447 |
|
|
2025
Q2 | $235K | Sell |
14,678
-3,333
| -19% | -$54K | ﹤0.01% | 2871 |
|
|
2025
Q1 | $274K | Sell |
18,011
-1,997
| -10% | -$32K | ﹤0.01% | 2798 |
|
|
2024
Q4 | $406K | Buy |
20,008
+7,025
| +54% | +$177K | ﹤0.01% | 2724 |
|
|
2024
Q3 | $334K | Buy |
12,983
+3,680
| +40% | +$61.4K | ﹤0.01% | 2670 |
|
|
2024
Q2 | $120K | Buy |
+9,303
| New | +$150K | ﹤0.01% | 3053 |
|
|
2023
Q2 | – | Sell |
-1,415
| Closed | -$26.6K | – | 3929 |
|
|
2023
Q1 | $26.6K | Buy |
1,415
+538
| +61% | +$8.87K | ﹤0.01% | 3681 |
|
|
2022
Q4 | $8.94K | Buy |
877
+16
| +2% | +$257 | ﹤0.01% | 3863 |
|
|
2022
Q3 | $23K | Sell |
861
-150
| -15% | -$5.46K | ﹤0.01% | 3749 |
|
|
2022
Q2 | $46K | Sell |
1,011
-146
| -13% | -$11.5K | ﹤0.01% | 3785 |
|
|
2022
Q1 | $114K | Sell |
1,157
-138
| -11% | -$12.9K | ﹤0.01% | 3539 |
|
|
2021
Q4 | $198K | Buy |
1,295
+767
| +145% | +$113K | ﹤0.01% | 3393 |
|
|
2021
Q3 | $72K | Sell |
528
-1
| -0.2% | -$137 | ﹤0.01% | 4021 |
|
|
2021
Q2 | $78K | Buy |
+529
| New | +$81K | ﹤0.01% | 4215 |
|
Deutsche Bank's TRML Position: Q4 2025 in Review
Deutsche Bank sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 12,730 shares — an estimated $609K sold.
Deutsche Bank first reported a position in TRML in Q2 2021 and held it in 14 quarters. The position peaked at $609K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Deutsche Bank reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Deutsche Bank sold 12,730 Tourmaline Bio shares in Q4 2025, an estimated $609K.
- Deutsche Bank first reported a position in Tourmaline Bio in Q2 2021 and held it in 14 quarters.
- Deutsche Bank's Tourmaline Bio position peaked at $609K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Deutsche Bank's 13F filing for Q4 2025, filed 11 Feb 2026.